Discussion about this post

User's avatar
Neural Foundry's avatar

This technical analysis on MRUS turned out to be really timley! The cup and handle breakout you identified in July at the 64.9 level was a great call, especially since Genmab ended up acquiring Merus at $97 per share in October. Your price target of 110 wasn't far off at all. The fact that you caught this as a Mid Cap Value play with that bullish continuation pattern speaks to the quality of the chart work. Really solid identificaton of the immuno-oncology space before the M&A action heated up.

Expand full comment
RASİM KOŞAR's avatar

Teşekkürler Roy

Expand full comment

No posts